[Effects of continuous adenosine infusion on pulmonary hypertension in chronically hypoxic rats]. 2008

Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
Department of Pediatrics, Clinical Division, Fuzhou General Hospital of Nanjing Command, Fuzhou 350025, China.

OBJECTIVE To observe the effects of continuous subcutaneous adenosine infusion on pulmonary hypertension in chronically hypoxic rats. METHODS Twenty-four SD rats were randomized into normoxic group, hypoxic group and adenosine-treated hypoxic group. Hypoxic environment was simulated in a chamber filled with 10% oxygen and 90% nitrogen. After 7 days of hypoxia, adenosine were administered subcutaneously in the rats in adenosine-treated group at the rate of 100 microg kg(-1) min(-1) via an Alzet micro-osmotic pump for 14 days, while the pumps in the other two groups contained normal saline. After 21 days of hypoxia, pulmonary artery pressure and tail-cuff blood pressure were measured, with the plasma rennin activity (RA), angiotensin II (AngII), endothelin (ET)-1, and nitric oxide (NO) determined. Inducible nitric oxide synthase (iNOS) expression in the pulmonary artery of the rats was detected using immunohistochemical method. RESULTS The mean pulmonary artery pressure (mPAP) was significantly higher in the hypoxic group than that in the normoxic group (P<0.01) and in the adenosine-treated group (P<0.01). Plasma ET-1 was significantly higher but plasma NO significantly lower in the hypoxic group than in the normoxic group (P<0.01) and the adenosine-treated group (P<0.01). iNOS expression in the pulmonary artery was higher in the hypoxic group than in normoxic group (P<0.01), and adenosine significantly increased iNOS expression in comparison with the normoxic and hypoxic groups (P<0.01). Plasma RA and AngII in the hypoxic group were significantly higher than those in the normoxic group (P<0.01) and the adenosine-treated (P<0.01). CONCLUSIONS Adenosine administered by continuous subcutaneous infusion alleviates chronically hypoxia-induced pulmonary hypertension in rats, in which rennin angiotensin system, ET-1, and iNOS/NO play a role.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000860 Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. Anoxia,Oxygen Deficiency,Anoxemia,Deficiency, Oxygen,Hypoxemia,Deficiencies, Oxygen,Oxygen Deficiencies
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
May 2017, International journal of molecular sciences,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
August 1994, The Journal of clinical investigation,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
April 1984, Respiration physiology,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
July 2003, American journal of physiology. Lung cellular and molecular physiology,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
July 2003, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
January 2004, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
December 1996, Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
March 1996, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
March 1997, The American journal of physiology,
Jian-Xin Tan, and Xin-Min Chen, and Xin Fang, and Meng-Jie Tao, and Xiu-Lan Huang
November 1996, Chinese medical journal,
Copied contents to your clipboard!